Revvity (NYSE:RVTY) Stock: Insider Maxwell Krakowiak Sells 1,631 Shares

Revvity Inc. (NYSE:RVTY) insider Maxwell Krakowiak sold 1,631 shares of the company’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total transaction of $235,728.43. Following the sale, the insider directly owned 14,781 shares of the company’s stock, valued at approximately $2,136,297.93. This represents a 9.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Revvity Stock Performance

NYSE:RVTY opened at $150.96 on Friday. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $152.26. The firm’s fifty day simple moving average is $123.32 and its 200 day simple moving average is $106.18. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $16.85 billion, a PE ratio of 71.88, a PEG ratio of 2.61 and a beta of 1.09.

Revvity (NYSE:RVTY) last released its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. During the same quarter in the previous year, the business earned $1.18 EPS. The business’s revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts anticipate that Revvity Inc. will post 5.36 EPS for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s payout ratio is currently 13.33%.

Key Headlines Impacting Revvity

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: The new test provides a commercial and strategic catalyst for Revvity (RVTY), strengthening its position in reproductive health and disease-risk diagnostics. The announcement was cited as the main reason shares moved higher and helped keep the stock near its 52-week high. Revvity Shares Rise on Launch of Child Type 1 Diabetes Screening Test
• Positive Sentiment: The recent operating backdrop is supportive: Revvity’s latest quarterly EPS of $1.41 exceeded the $1.21 consensus estimate, while revenue also topped expectations. The company maintained fiscal 2026 EPS guidance of $5.30–$5.40. Why Revvity Is Getting Attention Today
• Neutral Sentiment: Goldman Sachs continues to rate Revvity “Hold,” reflecting a cautious view despite the product news. The stock’s elevated valuation and strong run above its 50-day and 200-day moving averages may limit additional upside unless earnings growth accelerates. Goldman Sachs Remains a Hold on Revvity
• Negative Sentiment: Insider Maxwell Krakowiak sold 1,631 shares for approximately $235,728, reducing his direct ownership by 9.94%. The sale is relatively small and may be routine, but it is a modest sentiment headwind following the stock’s recent advance. Revvity Insider Sells 1,631 Shares

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada began coverage on Revvity in a research report on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 price objective for the company. Weiss Ratings upgraded shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. Sanford C. Bernstein initiated coverage on shares of Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 price target for the company. Wall Street Zen lowered shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Finally, KeyCorp lifted their target price on Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a research report on Friday, September 4th. Four investment analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. Based on data from MarketBeat.com, Revvity presently has a consensus rating of “Hold” and an average target price of $116.57.

Institutional Investors Weigh In On Revvity

Institutional investors and hedge funds have recently made changes to their positions in the company. EdgePoint Investment Group Inc. increased its position in Revvity by 3.1% in the 1st quarter. EdgePoint Investment Group Inc. now owns 8,800,863 shares of the company’s stock valued at $771,044,000 after acquiring an additional 265,204 shares in the last quarter. Jupiter Topco LLC acquired a new position in shares of Revvity during the second quarter worth approximately $961,017,000. Janus Henderson Group PLC lifted its position in shares of Revvity by 2.3% during the first quarter. Janus Henderson Group PLC now owns 8,348,127 shares of the company’s stock worth $731,386,000 after purchasing an additional 186,956 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Revvity during the second quarter valued at approximately $852,070,000. Finally, State Street Corp grew its stake in shares of Revvity by 0.8% during the second quarter. State Street Corp now owns 4,342,739 shares of the company’s stock valued at $483,173,000 after purchasing an additional 32,426 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.